 Life Science Investor Mandates
(Mar. 15 - Mar. 21
)
|
|
|
|
|
Backed by China and Taiwan Companies Invests Broadly Across Seed and Post-Seed Stage Life Science Companies
|
|
Invests Globally in Disruptive Medtech and Digital Health Companies in Trauma and Orthopedic Surgeries
|
|
Funding to Medtech, Cleantech, and IT Sectors Across North America, With Canadian Focus
|
|
Seeks Early-Stage Single Asset/Platform Technologies in Therapeutics and Revenue-Generating Medtech Companies
|
|
LSN's Sourcing & Ranking Service (SRS) provides clients with an opportunity to quickly source, vet, rank and engage with partners that are licensing global technology assets.
|
|
Click to see investors that are a fit for your product and stage of development
|
|
Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you
|
|
Click here if you want to receive free, targeted early stage dealflow for your life science investment firm
|
|
 |
|
 On April 10th, the 3rd annual RESI on MaRS conference will bring over 300 early stage life science investors into the Toronto ecosystem. The Life Science Nation Investor Research team thoroughly vets each of these investors, and collects detailed information on their focus sectors and investment criteria. Below are some of the firms who will be at the MaRS Discovery District in three weeks, separated by sector of interest. Click here to register for the conference.
|
Life Science Cross-Domain Investors
(Biotech, Medtech, Diagnostic & Digital Health)
|
|
Digital Health and Related Technologies
|
|
 |
|
Large corporations, especially in the pharmaceutical/biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation - an exit partner. However, attracting and concentrating talent, and providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.
Toronto, looking to ramp up commercialization of its world-class research and put its name on the map as a life science powerhouse, will host the RESI conference for the third time as a part of the Toronto Health Innovation Week and welcome a panel of Corporate Venture investors. This increasingly important investor class will discuss trends in the space, their current interests, and how entrepreneurs can best prepare to pitch to and work with a group like theirs.
Moderated by Salim Teja, President, Venture Services, MaRS Discovery District, this panel will feature:
- Marian Nakada, VP of Venture Investing, Johnson & Johnson
- Jens Eckstein, President, SR One
- Richard Osborn, Managing Partner, TELUS Ventures
- Tom Gibbs, Director, Debiopharm Innovation Fund
By registering for RESI on MaRS, you'll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences...
|
|
 Medical device innovation is known for being a challenging area for raising capital. Given the timelines and capital requirements involved, as well as the increasing consolidation of the major firms that make up the exit landscape for devices, entrepreneurs may find it difficult to build their investment story. However, LSN is in contact with hundreds of investors who are seeking deals in the device space, either for purely return-driven investments or for adding to a strategic pipeline. At RESI, we aim to bridge the gap between early stage device firms and investors and help entrepreneurs close those 'last three feet' to make deals.
At RESI on MaRS, we welcome a Medical Device Investors panel featuring experienced investors from across North America, including both strategic players and financially-driven venture investors who will explore and elucidate the world of early stage device investment from every angle. The panel will be moderated by Sam Ifergan, President & CEO, iGan Partners, and the participants are:
- Katherine Parra Moreno, Vice President of Business Development, Epic Capital Management
- Zishan Haroon, Chairman and General Partner, Julz Co LLC
- V Kadir Kadhiresan, Vice President, Venture Investments, Johnson & Johnson Innovation
- Gerry Brunk, Managing Director, Lumira Capital
|
|
|
Created & Produced by
|
 |
|
|
|
